Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMBRELLA C extension study of atezolizumab supply in prior Roche/Genentech trial participants
CTR20211862Phase 3Active
- Sponsor
- Roche
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), sponsored by Roche. Started Dec 2021; status: active.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)hepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20211862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211862.